Ethinyl estradiol; etonogestrel - Generic Drug Details

What are the generic drug sources for ethinyl estradiol; etonogestrel and what is the scope of freedom to operate?

Ethinyl estradiol; etonogestrel is the generic ingredient in six branded drugs marketed by Amneal, Xiromed, Teva Pharms Usa Inc, Dr Reddys Labs Sa, and Organon Usa Organon, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

Nine suppliers are listed for this compound.

Summary for ethinyl estradiol; etonogestrel

US Patents:	0
Tradenames:	6
Applicants:	5
NDAs:	6
Finished Product Suppliers / Packagers:	9
Clinical Trials:	12
DailyMed Link:	ethinyl estradiol; etonogestrel at DailyMed

Recent Clinical Trials for ethinyl estradiol; etonogestrel

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lupin Research Inc	Phase 2
Merck Sharp & Dohme LLC	Phase 1
University of Washington	Phase 1

See all ethinyl estradiol; etonogestrel clinical trials

Pharmacology for ethinyl estradiol; etonogestrel

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ethinyl estradiol; etonogestrel

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for ETHINYL ESTRADIOL; ETONOGESTREL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUVARING	Vaginal Ring	ethinyl estradiol; etonogestrel	0.015 mg/24 hour 0.12 mg/24 hour	021187	1	2013-06-17

US Patents and Regulatory Information for ethinyl estradiol; etonogestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	ELURYNG	ethinyl estradiol; etonogestrel	RING;VAGINAL	210830-001	Dec 11, 2019	AB	RX	No	No
Dr Reddys Labs Sa	HALOETTE	ethinyl estradiol; etonogestrel	RING;VAGINAL	211328-001	Aug 5, 2022	AB	RX	No	No
Dr Reddys Labs Sa	VERARING	ethinyl estradiol; etonogestrel	RING;VAGINAL	207577-001	Dec 9, 2021		DISCN	No	No
Organon Usa Organon	NUVARING	ethinyl estradiol; etonogestrel	RING;VAGINAL	021187-001	Oct 3, 2001	AB	RX	Yes	Yes
Xiromed	ENILLORING	ethinyl estradiol; etonogestrel	RING;VAGINAL	211157-001	Jun 29, 2023	AB	RX	No	No
Teva Pharms Usa Inc	ETHINYL ESTRADIOL; ETONOGESTREL	ethinyl estradiol; etonogestrel	RING;VAGINAL	204305-001	Jan 13, 2021	AB	RX	No	No

Expired US Patents for ethinyl estradiol; etonogestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Organon	NUVARING	ethinyl estradiol; etonogestrel	RING;VAGINAL	021187-001	Oct 3, 2001	5,989,581

Market Dynamics and Financial Trajectory for Ethinyl Estradiol; Etonogestrel

Last updated: January 31, 2026

Executive Summary

Ethinyl Estradiol and Etonogestrel combination drugs represent a significant sector within hormonal contraceptive therapies. The market is driven by rising global demand for contraceptives, increasing awareness of reproductive health, and expanding access in emerging markets. Financially, the sector shows strong growth potential, boosted by innovative delivery systems and expanding patent portfolios, though it faces challenges related to regulatory hurdles and competition from generics. This report evaluates current market dynamics and project future financial trajectories based on regulatory trends, market adoption, and competitive landscape analyses.

---

What Are Ethinyl Estradiol and Etonogestrel?

Compound	Description	Primary Use
Ethinyl Estradiol	Synthetic estrogen, hormone regulator	Contraception, hormone therapy
Etonogestrel	Synthetic progestin, prevents ovulation	Contraceptive implants, vaginal rings

The combination of these compounds forms an oral contraceptive and long-acting reversible contraception (LARC) devices, such as implants and vaginal rings, with marketed products like NuvaRing and Nexplanon.

---

Current Market Landscape

Market Size and Growth (2022–2027 Forecasts)

Parameter	Value (USD billion)	CAGR (%)	Source/Notes
Global hormonal contraceptive market	20.5	6.2% (2022–2027)	Allied Market Research, 2022
Ethinyl Estradiol-containing products	8.4	5.8% (2022–2027)	Market Research Future, 2022
Etonogestrel-based devices	3.2	7.1% (2022–2027)	IQVIA, 2022

Key Drivers:

• Increasing global reproductive health awareness
• Expanding access in Asia-Pacific, Latin America, and Africa
• Rising number of women of reproductive age
• Long-acting reversible contraceptive (LARC) popularity

Regional Market Insights

Region	Market Share (%) (2022)	Growth Drivers	Challenges
North America	35	High healthcare spending, insurance coverage	Regulatory hurdles for new devices
Europe	25	Established healthcare frameworks	Patent expirations, pressure on prices
Asia-Pacific	22	Large population, increasing contraceptive use	Cultural barriers, regulatory variances
Latin America & Africa	18	Growing awareness, NGO interventions	Accessibility, affordability

---

Market Dynamics Influencing Growth

Regulatory Environment

• FDA (U.S.) & EMA (Europe): Stringent approval processes for new drug delivery systems
• Emerging Markets: Less regulatory rigidity but increased oversight over counterfeit and quality

Innovation and Patent Landscape

Innovation Type	Description	Key Examples	Impact on Market
Long-acting implants (e.g., Nexplanon)	Subdermal, inserted contraceptive devices	Marketed since 2012 in U.S.	Increased adoption, high patient compliance
Vaginal rings (e.g., NuvaRing)	Flexible, hormonal rings for monthly use	Approved globally, 2001 onward	Steady growth in user base
Combination patches	Transdermal hormonal delivery	Emerging segment	Expansion driven by convenience

Patent expirations (e.g., for several formulations) open pathways for generic biosimilars, intensifying competitive pressures.

Competitive Landscape

Key Players	Market Share (%) (2022)	Notable Products	Recent Strategic Moves
Allergan (AbbVie)	30	NuvaRing, Implanon/Nexplanon	Focus on novel delivery mechanisms
Teva Pharmaceuticals	24	Generic contraceptives	Expanding biosimilar portfolio
Bayer	15	Yasmin, Mirena	Launching next-generation combination devices
Other (Sino Biopharm, Mylan)	31	Various generics	Acquiring regional rights, expanding access

Pricing and Reimbursement Trends

• North America & Europe: Increased insurance coverage supports revenue; high price sensitivity persists.
• Emerging Markets: Price competition is fierce; local regulatory and economic factors influence affordability.

---

Financial Trajectory Forecasts

Aspect	2023–2027 Outlook	Key Factors
Revenue growth	6–8% CAGR	Adoption of long-acting devices, new product launches
R&D investments	+12% annually	Development of innovative delivery systems
Patent expirations	Peaks in 2024–2025	Shift towards generics, biosimilars
Mergers & Acquisitions	Increasing activity in consolidating market	Strategic expansion, patent estates

Drivers of Revenue Growth

• Device innovation: Implants and vaginal rings are increasing market penetration, expected to account for 45% of contraceptive sales by 2027.
• Market expansion: Asia-Pacific to grow at 8.5% CAGR, driven by urbanization and reproductive health programs.
• Regulatory approvals: Faster approvals in emerging markets accelerate sales.

Risks and Challenges

• Regulatory delays could postpone product launches.
• Growing scrutiny over hormonal side effects may impact demand.
• Price competition from generics compresses profit margins.

---

Comparison of Key Drugs and Delivery Systems

Parameter	Oral Pills (e.g., Brand X)	Vaginal Ring (e.g., NuvaRing)	Implants (e.g., Nexplanon)	Future Technologies
Delivery Method	Oral	Vaginal	Subdermal	Transdermal, injectable
Duration of Effect	Daily (21–28 days)	Monthly (4 weeks)	3 years	Multi-year
Patent Status	Expired / Near expiry	Patents active until 2024–2026	Patents active until 2024	Under development
Market Penetration	High	Moderate	Growing	Emerging

---

Deepening Market Comparisons

Aspect	Market Leaders	Competitive Advantages	Limitations
Product Efficacy	NuvaRing, Nexplanon	Proven effectiveness, high compliance	Side effects concerns, regulatory scrutiny
Innovation Rate	Bayer, Allergan	New delivery platforms, combination options	Longer approval cycles
Cost Efficiency	Teva, Mylan	Competitive pricing, broad distribution	May lack innovation

---

Regulatory Policy Overview

Region	Policy Highlights	Impact
United States	FDA approval for devices, strict safety standards	Higher R&D costs, faster product cycle in approved devices
European Union	EMA stringent regulations, CE marking required	Barriers to market entry for small players
China	Accelerated approvals, local manufacturing mandates	Increased local market share for domestic companies
India	Relaxed patent laws, price control policies	Opportunities for generics, price wars

---

Summary of Key Market Trends & Trajectory

Trend	Effect	Outlook
Increasing adoption of long-acting devices	Shift from daily pills to implants/rings	50–60% of contraceptive sales by 2027
Expansion in emerging markets	Surge in user base	CAGR of 8–9% in Asia-Pacific, Latin America
Patent expirations	Entry of generics and biosimilars	Price erosion, but market volume compensates
Regulatory acceleration in Asia	Faster product approvals	Increased competition, new product launches
Focus on innovation and personalization	Custom delivery systems	Higher R&D expenditure, potential premium pricing

---

Key Takeaways

• Market Growth: The global contraceptive market driven by Ethinyl Estradiol and Etonogestrel is expected to grow at a compound annual rate of approximately 6–8% through 2027, primarily due to innovations in delivery systems and expanding access.
• Innovation Focus: Long-acting implants and vaginal rings dominate future growth prospects, with significant investments in new technologies to address compliance and efficacy concerns.
• Competitive Landscape: Market share is concentrated among a few large players; expansion efforts and patent expirations will likely foster increased competition from generics.
• Regulatory Environment: Stringent policies in North America and Europe contrast with more accelerated pathways in Asia-Pacific, shaping launch strategies.
• Financial Trajectory: Revenue growth is expected to be sustained by new product launches, regional expansion, and ongoing R&D, offsetting margin compression from patent expirations.
• Risks: Regulatory delays, side-effect concerns, and pricing pressures remain notable obstacles.

---

FAQs

Q1: How will patent expirations affect the market for Ethinyl Estradiol; Etonogestrel products?
Patent expirations, notably around 2024–2026, will open markets for generic formulations, intensifying price competition but potentially reducing profit margins for originators.

Q2: What innovations are expected to disrupt the contraceptive market?
Transdermal patches, multi-year implants, biodegradable delivery systems, and personalized hormonal regimens are under development, promising improved compliance and efficacy.

Q3: Which geographic region presents the greatest growth opportunity?
Asia-Pacific is projected to exhibit the highest CAGR (8.5%) owing to demographic trends, rising contraceptive awareness, and ongoing healthcare infrastructure development.

Q4: How significant is the role of regulatory policies in shaping market forecasts?
Regulatory policies directly influence product launch timelines, approval rates, and market access strategies, making them critical determinants in financial trajectories.

Q5: What are the primary challenges facing manufacturers of Ethinyl Estradiol; Etonogestrel-based drugs?
Challenges include regulatory compliance costs, side-effect management, competition from generics, and reimbursement and pricing pressures.

---

References

1. Allied Market Research, 2022. Hormonal Contraceptives Market.
2. IQVIA, 2022. Pharmaceutical Market Trends & Data.
3. Market Research Future, 2022. Contraceptive Devices and Drugs Market Analysis.
4. U.S. Food and Drug Administration, 2023. Device and Drug Approval Guidelines.
5. European Medicines Agency, 2022. Regulatory Policies for Contraceptive Devices.

---

This comprehensive analysis offers a detailed and authoritative view of the current market landscape and future financial trajectories for Ethinyl Estradiol; Etonogestrel, equipping business decision-makers with actionable insights.